assistant professor, cancer immunologist, bioinformatics and cancer genomics
New York, USA
Joined December 2020
- Tweets75
- Following86
- Followers58
- Likes24
Vladimir Roudko retweeted
Just heard the brilliant news that AlphaFold was awarded the lasker award- congratulation to Deemis Hassabis & team for a well deserved recognition laskerfoundation.org/winners…
Vladimir Roudko retweeted
Today we launch the next generation of AI oncology company with the support of great investors @hardimanjames @DCVC, @dreidco @ZettaVentures, 11.2, Intermountain Ventures, Epic Ventures, Catalio, North South Ventures, @viswacolluru @RecursionChris.
businesswire.com/news/home/2…
Vladimir Roudko retweeted
New generation of cancer-preventing vaccines enter early clinical trials for healthy people at high risk for disease #cancer #Immunotherapy
science.org/content/article/…
Vladimir Roudko retweeted
Storing and analyzing a genome on a blockchain genomebiology.biomedcentral.…
Vladimir Roudko retweeted
The @bernstein_lab is now on #Twitter! Follow us for lab updates and news on cancer epigenetics!!
🧬🔬
Vladimir Roudko retweeted
New updated analysis by the team at @CancerResearch in collaboration with @IQVIA_global of the PD1/PDL1 clinical trial landscape, including use of approved therapies in the clinic and a summary of new anti-PD1/PDL1 treatment modalities go.nature.com/3HIpHPm
Vladimir Roudko retweeted
The new @EMBL Programme has launched!
We're proud to be a part of @EMBL and we're looking forward to contributing our #bioinformatics expertise to this exciting new scientific programme that ushers in a new era in the life sciences.
EMBL embarks on a new era of molecular biology.
EMBL research will expand to study life in context – from molecules to ecosystems. Broad in scope, our next programme encompasses fundamental research, services & multidisciplinary collaboration.
embl.org/news/lab-matters/a-…
Vladimir Roudko retweeted
A study evaluating effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the #Omicron variant indicates a third dose neutralizes Omicron at a similar order of magnitude as was observed after two doses of the vaccine against wild-type #SARSCoV2. fcld.ly/d9noexp
Vladimir Roudko retweeted
MEFISTO is out in Nature Methods - a framework for dimension reduction and integration of multi-modal omics data with temporal or spatial resolution. Paper at nature.com/articles/s41592-0…, highlights in the thread below. (1/7)
Vladimir Roudko retweeted
(1) Finally out, after one of the most painful and long reviews (with nitpicky reviews, see my last comment) is a method that I am extremely proud of and excited about. One of the best in my career: nature.com/articles/s41592-0…
Vladimir Roudko retweeted
Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! nature.com/articles/s41589-0…
Vladimir Roudko retweeted
Studying ~56 million T cells from 55 COVID patients, researchers in @SciImmunology offer a high-res picture of epitope reactivity and TCR usage in CD8 T cells specific for #SARSCoV2, some of which also react to “common cold” coronaviruses. fcld.ly/s5bda4r
Vladimir Roudko retweeted
Highly recommended review! 🤯😍😍👏
Germinal Centre Shutdown frontiersin.org/article/10.3…
Vladimir Roudko retweeted
A new method developed to reread a single polypeptide many times overcomes one of the biggest obstacles toward single-molecule proteomics.
Read more in a new #SciencePerspective: fcld.ly/23d7ov4
Vladimir Roudko retweeted
Findings from the KEYNOTE-522 trial show the addition of the immunotherapy agent pembrolizumab to chemotherapy before surgery decreased the recurrence by almost 40% in patients with early triple-negative breast cancer. #TNBC
bit.ly/3yXPUGd
Vladimir Roudko retweeted
Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis dlvr.it/SFrY1K
Vladimir Roudko retweeted
Ever wanted to quickly make a #PROTAC degrader of a #TranscriptionFactor? Check out our latest generation of TRAFTACs- just a TF binding sequence dsDNA oligo coupled to our VHL ligand. PoC studies degraded Myc and #brachyury. biorxiv.org/content/10.1101/…
Vladimir Roudko retweeted
You can read part of my PhD research on a case of neurotoxicity after #BCMA CAR T in multiple #myeloma, published today in @NatureMedicine. Just in time for #ASH2021 I guess...! #mmsm nature.com/articles/s41591-0…
Vladimir Roudko retweeted
Online Now: Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings dlvr.it/SDdfLs
Vladimir Roudko retweeted
Ma et al describe TetTCR-SeqHD - a method to simultaneously profile TCR sequences, cognate antigen specificities, targeted gene-expression, and surface-protein expression from tens of thousands of single cells. rdcu.be/cBOXB
